Abstract: A dental scanning system comprises an intraoral scanner and one or more processors. The intraoral scanner comprises one or more light projectors configured to project a pattern (comprising a plurality of pattern features) on a surface of a dental object, and two or more cameras configured to acquire one or more sets of images, wherein each set of images comprises at least one image from each camera, and wherein each image includes at least a portion of the projected pattern. The processors are configured to determine one or more image features within each set of images, solve a correspondence problem within each set of images such that points in 3D space are determined based on the image features, wherein said points form a solution to the correspondence problem, and wherein the correspondence problem is solved for groups of pattern features, and generate a digital 3D representation of the dental object using the solution to the correspondence problem.

Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.

Abstract: An intraoral scanning system comprises and intraoral scanner and a processor. The intraoral scanner comprises one or more cameras and one or more structured light projectors, the intraoral scanner to generate a series of images using the one or more cameras, each image including at least a portion of a pattern projected by the one or more structured light projectors onto an intraoral three-dimensional surface. The processor runs a correspondence algorithm to compute respective three-dimensional positions of a plurality of features of the pattern on the intraoral three-dimensional surface, as captured in the series of images. The processor identifies the computed three-dimensional position of a detected feature of the pattern as corresponding to a particular projector ray r, in at least a subset of the series of images. The processor tracks the particular projector ray r across one or more additional images of the series of images.

Abstract: The present invention is directed to PVRIG polypeptides and their uses.

Abstract: The invention is a dust control substances-solution (DCSS). The invention discloses the substances the DCSS is made of, how they are to be mixed and how the DCSS is to be applied. The DCSS is based on treated soft wood particles and substances that form a layer oved dust covered surfaces. The layer “traps” water that is applied to the surface, thus, maintaining the dust in aggregates and prevents its raising to the air.

Abstract: A system for connecting cage-side connectors to PCB-side connectors. The system enables OSFP and QSFP pluggable modules to be connected to breakouts on PCBs within a networking device. The system includes one or more cage-side connectors connected via one or more cables to one or more PCB-side connectors. Keyed PCB-side connectors and unique lengths of cables ensure proper connections to headers on a PCB.

Abstract: The present invention is directed to PVRIG polypeptides and their uses.

Abstract: Provided herein are TLR7/8 agonists to enhance immune responses or for use as adjuvants in fentanyl vaccines in opioid-using individuals.

Abstract: A cable pillar is provided for use in a switch system. The cable pillar includes a cavity that enables a plurality of cables to pass from a first side to a second side of the cable pillar. For example, the cables may be routed from sets of access paths located in rails mounted on the sides of the cable pillar to enlarged access paths located near the top or bottom of the cable pillar. The enlarged access paths may be sized to receive every cable that passes through a set of access paths located on an opposing side of the cable pillar from a corresponding enlarged access path. Additionally, the cable pillar may be configured to releasably attach to a chassis of the switch system. In some examples, the plurality of cables accommodated by the cable pillar may serve as a cable backplane of the switch system.

Abstract: Provided herein are imidazopyrimidine compounds, such as compounds of Formula (I), for use in enhancing human immune response and/or as adjuvants in vaccines.

Abstract: Provided herein are adjuvantation systems for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen.

Abstract: Provided herein are thiazole amide compounds (e.g., Formula (I)) for use in enhancing human immune response and/or as adjuvants in vaccines. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are compositions (e.g., pharmaceutical composition), kits, methods, and uses including or using compounds described herein.

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Provided herein are Stimulator of Interferon Genes (STING) ligand for use in enhancing immune response and/or as adjuvants in vaccines. In some embodiments, STING ligand is used alone or in combination with Alum in an adjuventation system for early life immunization.

Abstract: A processor includes a counter to store a cycle count that tracks a number of cycles between retirement of a first branch instruction and retirement of a second branch instruction during execution of a set of instructions. The processor further includes a stack of registers coupled to the counter, wherein the stack of registers is to store branch type information including: a first value of the counter when the first branch instruction is retired; a second value of the counter when the second branch instruction is retired; a first type information value indicating a type of the first branch instruction; and a second type information value indicating a type of the second branch instruction.

Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.

Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: The present invention relates to an anti-ILDR2 antibody, a fragment or derivative thereof, a modified antibody format, or an antibody mimetic for use in combination with a PD-1 antagonist in the treatment of cancer. Other aspects of the present invention relate to a combination comprising an anti-ILDR2 antibody and a PD-1 antagonist and the use of such combination as a medicament, as well as methods of treatment or prophylaxis of a cancer in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies as described herein. Further, the present invention relates to a kit comprising anti-ILDR2 antibodies and PD-1 antagonists and optionally one or more further pharmaceutical agents.